¼¼°èÀÇ Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VEGF) ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2031³â)
Vascular Endothelial Growth Factor Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»óǰÄÚµå : 1475887
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 440 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,555,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,291,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VEGF) ½ÃÀåÀº ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú ´Ù¾çÇÑ Ç÷°ü °ü·Ã Áúȯ ¹× »óŸ¦ Ä¡·áÇϱâ À§ÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ±Ù ¸î ³âµ¿¾È Å« °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇп¡ ´ëÇØ ÀÚ¼¼È÷ Á¶»çÇÏ°í ½ÃÀå ±Ô¸ð, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, °æÀï ȯ°æ¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» ´ã°í ÀÖ½À´Ï´Ù. ºÐ¼® ±â°£Àº 2024³âºÎÅÍ 2031³â±îÁöÀ̸ç, ÀÌÇØ°ü°èÀڵ鿡°Ô Àü·«Àû ÀÇ»ç°áÁ¤°ú »ç¾÷ ¼ºÀå¿¡ µµ¿òÀÌ µÇ´Â ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è VEGF ½ÃÀåÀº 2024-2031³â CAGR 10.7%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³â ½ÃÀå ±Ô¸ð´Â 2¾ï 6,170¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2031³â¿¡´Â 5¾ï 3,311¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

VEGF ½ÃÀå - º¸°í¼­ ¹üÀ§ :

ÀÌ Á¶»ç º¸°í¼­´Â VEGF ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÏ°í ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ» °­Á¶Çϸç, VEGF´Â »õ·Î¿î Ç÷°üÀ» Çü¼ºÇÏ´Â °úÁ¤ÀÎ Ç÷°ü½Å»ý¿¡¼­ ±× ¿ªÇÒ·Î ÀÎÇØ Ç×¾Ï Ä¡·áÀÇ Áß¿äÇÑ Ç¥ÀûÀÔ´Ï´Ù. Ç× VEGF Ä¡·á´Â ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï°ú ³ëÈ­ °ü·Ã Ȳ¹Ýº¯¼º(AMD), ´ç´¢¸Á¸·º´Áõ ¹× ±âŸ ¸Á¸· ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾Ï°ú ³ëÈ­ °ü·Ã ÁúȯÀÇ ¹ß»ý·ü Áõ°¡¿Í ÀÇÇÐ ¿¬±¸ ¹× Ä¡·á¹ýÀÇ ¹ßÀüÀº VEGF Ç¥Àû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :

¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·ü Áõ°¡´Â VEGF ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¾Ï¼¼Æ÷ÀÇ ¼ºÀå°ú ÀüÀÌ¿¡ »õ·Î¿î Ç÷°üÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ç× VEGF Ä¡·á´Â ´Ù¾çÇÑ ¾Ï Ä¡·áÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AMD¿Í °°Àº ³ëÈ­ °ü·Ã ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾à¹° Àü´Þ ½Ã½ºÅÛ ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ ±â¼ú ¹ßÀüÀº º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á¹ýÀ¸·Î À̾îÁ® ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Ä¡·á¹ý °³¼±°ú VEGF ¾ïÁ¦Á¦ÀÇ »õ·Î¿î ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

ÀáÀç·Â¿¡µµ ºÒ±¸Çϰí VEGF ½ÃÀåÀº ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Ç× VEGF Ä¡·á´Â °í°¡À̱⠶§¹®¿¡ ƯÈ÷ ÀÇ·á ½Ã½ºÅÛÀÌ ¹ß´ÞÇÏÁö ¾ÊÀº Áö¿ª¿¡¼­´Â ÀϺΠȯÀÚÀÇ Á¢±Ù¼ºÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, VEGF ¾ïÁ¦Á¦ÀÇ ºÎÀÛ¿ëÀº °íÇ÷¾Ð, »óó Ä¡À¯ Àå¾Ö¿Í °°Àº ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ ȯÀÚ¿¡°Ô À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮°ú ±ä ½ÂÀÎ ÀýÂ÷µµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ´ëü ¿ä¹ý°úÀÇ °æÀï°ú °áÇÕÇÏ¿© ½ÃÀå È®´ë¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ :

VEGF ½ÃÀå¿¡´Â ¼ºÀå°ú Çõ½ÅÀÇ Å« ±âȸ°¡ ÀÖ½À´Ï´Ù. Ç× VEGF Ä¡·áÁ¦ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× Á¦³×¸¯ ÀǾàǰÀÇ °³¹ßÀº ´õ Àú·ÅÇÑ Ä¡·á¹ýÀÇ ±æÀ» ¿­¾î ´õ ¸¹Àº ȯÀÚ±º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϰí, VEGF ¾ïÁ¦Á¦ÀÇ »õ·Î¿î Ä¡·á ¿ëµµ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ½ÃÀå ´Ù°¢È­ °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ °øµ¿¿¬±¸´Â ȹ±âÀûÀÎ Ä¡·á¹ýÀ» âÃâÇϰí VEGF ½ÃÀåÀÇ Àúº¯À» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ´Â ½ÃÀå È®´ëÀÇ ¶Ç ´Ù¸¥ ±âȸÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÁÖ¿ä ³»¿ë

Á¦5Àå ½ÃÀå ¹è°æ

Á¦6Àå COVID-19 À§±â ºÐ¼®

Á¦7Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ¼ö¿ä(±Ý¾× ¶Ç´Â ±Ô¸ð) ºÐ¼®

Á¦8Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : VEGF À¯Çüº°

Á¦9Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : VGEF ¿ëµµº°

Á¦10Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : ¹ßÇö ¼÷ÁÖº°

Á¦11Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦13Àå ºÏ¹ÌÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦15Àå À¯·´ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦16Àå ³²¾Æ½Ã¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦17Àå µ¿¾Æ½Ã¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦18Àå ¿À¼¼¾Æ´Ï¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦19Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®

Á¦20Àå ½ÃÀå ±¸Á¶ ºÐ¼®

Á¦21Àå °æÀï ºÐ¼®

Á¦22Àå »ç¿ëµÈ ÀüÁ¦Á¶°Ç°ú µÎÀÚ¾î

Á¦23Àå Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Vascular Endothelial Growth Factor (VEGF) market has gained significant traction in recent years, driven by advances in medical research and the growing need for effective therapies to treat a range of vascular-related diseases and conditions. This comprehensive report from Persistence Market Research delves into the dynamics of the VEGF market, providing key insights into market size, growth drivers, challenges, opportunities, and competitive landscape. The analysis covers the period from 2024 to 2031, offering stakeholders valuable information to guide their strategic decisions and business growth.

The global VEGF market is projected to expand at a CAGR of 10.7% from 2024 to 2031, with a market value estimated at USD 261.7 million in 2024 and expected to reach USD 533.1 million by 2031.

Key Insights:

VEGF Market - Report Scope:

The report provides a comprehensive analysis of the VEGF market, highlighting key factors driving growth. VEGF is a significant target for anti-cancer therapies due to its role in angiogenesis, the process of forming new blood vessels. Anti-VEGF therapies are used to treat various types of cancers, as well as other conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases. The growing incidence of cancer and age-related diseases, coupled with advancements in medical research and treatment methods, has fueled demand for VEGF-targeting therapies.

Market Growth Drivers:

The increasing prevalence of cancer worldwide is a major driver for the VEGF market. As cancer cells require new blood vessels to grow and spread, anti-VEGF therapies have become a cornerstone in the treatment of various cancers. Additionally, the rising incidence of age-related diseases, such as AMD, has further contributed to market growth. Technological advancements in drug delivery systems and personalized medicine approaches have led to more effective and targeted therapies, fostering market expansion. The demand for improved treatments and the development of new applications for VEGF inhibitors are key factors driving the market's growth.

Market Restraints:

Despite its potential, the VEGF market faces certain challenges. The high cost of anti-VEGF therapies can limit access for some patients, especially in regions with less developed healthcare systems. Additionally, side effects associated with VEGF inhibitors, such as hypertension and impaired wound healing, can pose risks to patients. Regulatory hurdles and the lengthy process of drug approval also impact market growth. These factors, combined with competition from alternative therapies, can restrain the market's expansion.

Market Opportunities:

The VEGF market presents significant opportunities for growth and innovation. The development of biosimilars and generic versions of anti-VEGF therapies offers a pathway to more affordable treatments, expanding access to a broader patient base. Ongoing research into new therapeutic applications for VEGF inhibitors provides potential for market diversification. Furthermore, collaborations between pharmaceutical companies and research institutions can lead to groundbreaking treatments and expand the VEGF market's reach. Investment in emerging markets, where demand for advanced therapies is growing, represents another opportunity for market expansion.

Key Questions Addressed in the Report:

Competitive Landscape and Business Strategies:

The VEGF market features a competitive landscape with leading players like Genentech, Regeneron Pharmaceuticals, and Amgen. These companies focus on innovation, research and development, and strategic collaborations to maintain their market position. Genentech's Avastin, a widely used anti-VEGF drug, is a prominent example of a successful product in this sector. Regeneron Pharmaceuticals has also gained a significant market share with its product Eylea, used in the treatment of AMD and other retinal diseases.

Key business strategies include the development of new drug formulations, expansion into new therapeutic areas, and partnerships with other pharmaceutical companies. Companies are also focusing on expanding their presence in emerging markets and exploring biosimilar opportunities to increase their market reach.

Key Companies Profiled:

VEGF Market Segmentation:

VEGF Market by VEGF Type:

VEGF Market by Expression Host:

VEGF Market by Application:

VEGF Market by End User:

Research Centers & Laboratories

Hospital-attached Laboratories (HALs)

VEGF Market by Region:

Table of Contents

1. Executive Summary

2. Market Overview

3. Key Market Trends

4. Key Inclusions

5. Market Background

6. COVID-19 Crisis Analysis

7. Global Vascular Endothelial Growth Factor (VEGF) Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

8. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Types

9. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VGEF Application

10. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Expression Hosts

11. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by End User

12. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by Region

13. North America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

14. Latin America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

15. Europe Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

16. South Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

17. East Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

18. Oceania Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

19. Middle East and Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

20. Market Structure Analysis

21. Competition Analysis

22. Assumptions and Acronyms Used

23. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â